Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bilgin

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|March 25, 2026
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphomaYvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, et al.
Haematologica|April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyMarie José Kersten, Martin Dreyling, Kim M Linton, et al.
Therapeutic Advances in Hematology|March 16, 2023
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registryMonia Marchetti, Jon Salmanton-García, Shaimaa El-Ashwah, et al.
Leukemia & Lymphoma|November 15, 2023
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA surveyShaimaa El-Ashwah, Jon Salmanton-García, Yavuz M Bilgin, et al.
American Journal of Hematology|June 15, 2022
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey reportOla Blennow, Jon Salmanton-García, Piotr Nowak, et al.
Frontiers in Oncology|October 24, 2022
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, et al.
Cancers|November 26, 2022
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha SurveyChiara Cattaneo, Jon Salmanton-García, Francesco Marchesi, et al.
Open Forum Infectious Diseases|March 19, 2026
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA RegistryJon Salmanton-García, Francesco Marchesi, Erica Mackenzie, et al.
Eclinicalmedicine|April 12, 2023
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Maria Gomes da Silva, et al.
Blood|September 20, 2022
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA surveyLivio Pagano, Jon Salmanton-García, Francesco Marchesi, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|March 25, 2026
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphomaYvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, et al.
Haematologica|April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyMarie José Kersten, Martin Dreyling, Kim M Linton, et al.
Therapeutic Advances in Hematology|March 16, 2023
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registryMonia Marchetti, Jon Salmanton-García, Shaimaa El-Ashwah, et al.
Leukemia & Lymphoma|November 15, 2023
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA surveyShaimaa El-Ashwah, Jon Salmanton-García, Yavuz M Bilgin, et al.
American Journal of Hematology|June 15, 2022
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey reportOla Blennow, Jon Salmanton-García, Piotr Nowak, et al.
Frontiers in Oncology|October 24, 2022
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, et al.
Cancers|November 26, 2022
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha SurveyChiara Cattaneo, Jon Salmanton-García, Francesco Marchesi, et al.
Open Forum Infectious Diseases|March 19, 2026
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA RegistryJon Salmanton-García, Francesco Marchesi, Erica Mackenzie, et al.
Eclinicalmedicine|April 12, 2023
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Maria Gomes da Silva, et al.
Blood|September 20, 2022
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA surveyLivio Pagano, Jon Salmanton-García, Francesco Marchesi, et al.
Pageof 8